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Background: Atherosclerotic renal artery stenosis (ARAS) is common in cardiovascular diseases and associated with
hypertension, renal dysfunction and/or heart failure. There is a paucity of data about the prevalence and the role of
ARAS in the pathophysiology of combined chronic heart failure (CHF) and chronic kidney disease (CKD). We
investigated the prevalence in patients with combined CHF/CKD and its association with renal function, cardiac
dysfunction and the presence and extent of myocardial fibrosis.
Methods: The EPOCARES study (ClinTrialsNCT00356733) investigates the role of erythropoietin in anaemic patients
with combined CHF/CKD. Eligible subjects underwent combined cardiac magnetic resonance imaging (cMRI),
including late gadolinium enhancement, with magnetic resonance angiography of the renal arteries (MRA).
Results: MR study was performed in 37 patients (median age 74 years, eGFR 37.4 ± 15.6 ml/min, left ventricular
ejection fraction (LVEF) 43.3 ± 11.2%), of which 21 (56.8%) had ARAS (defined as stenosis >50%). Of these 21
subjects, 8 (21.6%) had more severe ARAS >70% and 8 (21.6%) had a bilateral ARAS >50% (or previous bilateral
PTA). There were no differences in age, NT-proBNP levels and medication profile between patients with ARAS
versus those without. Renal function declined with the severity of ARAS (p = 0.03), although this was not
significantly different between patients with ARAS versus those without. Diabetes mellitus was more prevalent in
patients without ARAS (56.3%) against those with ARAS (23.8%) (p = 0.04). The presence and extent of late
gadolinium enhancement, depicting myocardial fibrosis, did not differ (p = 0.80), nor did end diastolic volume
(p = 0.60), left ventricular mass index (p = 0.11) or LVEF (p = 0.15). Neither was there a difference in the presence of
an ischemic pattern of late enhancement in patients with ARAS versus those without.
Conclusions: ARAS is prevalent in combined CHF/CKD and its severity is associated with a decline in renal function.
However, its presence does not correlate with a worse LVEF, a higher left ventricular mass or with the presence and
extent of myocardial fibrosis. Further research is required for the role of ARAS in the pathophysiology of combined
chronic heart and renal failure.
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The combination of chronic heart failure (CHF) and
chronic kidney disease (CKD) is prevalent and associated
with a high cardiovascular mortality and morbidity [1-3].
Both CHF and CKD can be caused by atherosclerosis.
Renal artery stenosis is often of atherosclerotic aetiology
and can manifest itself by hypertension, progressive
renal dysfunction, flash pulmonary oedema as well as
congestive heart failure [4-6]. Furthermore, it is often
diagnosed without evident clinical symptoms. The
prevalence of atherosclerotic renal artery stenosis
(ARAS) is prevalent in cardiovascular diseases; its preva-
lence is approximately 15% in patients with proven cor-
onary artery disease and it is up to 40% in patients with
end stage renal disease [7]. However, only very few stud-
ies have determined the prevalence of ARAS in patients
with combined CHF and CKD.
In CHF, in several observational studies, patients
with ARAS had prolonged hospital admissions and a
higher mortality rate [8-10]. This finding is in agree-
ment with reports that the presence of ARAS is asso-
ciated with systemic atherosclerosis [11], reduced renal
filtration and perfusion and with cardiac abnormalities.
However, few data are known about its association
with cardiac abnormalities. In an echocardiography
study the majority of patients with proven ARAS had
cardiac abnormalities, mostly consisting of diastolic
dysfunction and left ventricular hypertrophy [12]. To
our knowledge, no data are known about its possible
association with the presence and extent of myocardial
fibrosis, potentially reflecting an increased risk of sud-
den cardiac death. Although the concurrence of ARAS
and cardiac abnormalities may play a role in the cardi-
orenal syndrome, there are few data to substantiate
this and the prevalence of ARAS in combined CKD
and CHF is unknown.
We hypothesized that ARAS is prevalent in patients
with combined CKD and CHF and that its presence is
associated with a worse renal function, more severe car-
diac dysfunction and the presence and extent of myocar-
dial fibrosis. Therefore we assessed, in anaemic patients
with combined heart and renal failure: 1. The prevalence
of ARAS and 2. The association of ARAS with renal and
cardiac dysfunction and the presence of myocardial fi-
brosis. We used cardiac magnetic resonance imaging
(cMRI) for this purpose, as the quantitative values for
cardiac volumes, left ventricular mass and function are
more accurate than with echocardiography. In addition,
intravenous gadolinium contrast material can be used
both for magnetic resonance angiography (MRA) of the
aorta and the renal arteries, as well as for late gadolin-
ium enhanced (LGE) assessment of myocardial fibrosis,
thereby providing information about the underlying aeti-
ology of the cardiac dysfunction.Methods
Patient population
This study is a sub study of the EPOCARES study
(ErythroPOietin in the CArdioREnal Syndrome, Clin-
Trials.Gov NCT 00356733). The study design has been
published elsewhere [13]. In short, the EPOCARES study
is an open-label, prospective, randomized trial, in which
patients with CHF, CKD (glomerular filtration rate
(GFR) by Cockcroft-Gault equation of 20–70 ml/min)
and mild anaemia (haemoglobin 10.3-12.6 g/dL for men
and 10.3-11.9 g/dL for women) were included to test the
erythropoietic and non-erythropoietic responses to
erythropoietin (EPO) treatment. At baseline all patients
without cardiac implantable electronic devices under-
went combined cMRI and magnetic resonance angiog-
raphy (MRA) of the renal arteries. During the study
period, the concern about the association between cer-
tain gadolinium agents and nephrogenic systemic fibro-
sis surfaced, which led us to the decision to perform
cMRI/MRA only in patients with a GFR >30 ml/min. All
patients were on maximal tolerated dosages of a β-
blocker, angiotensin-converting enzyme (ACE) inhibitor
and/or an angiotensin receptor blocker according to
CHF guidelines. CHF was defined as NYHA class II or
III, based on symptoms and signs [14]. Both patients
with heart failure with reduced ejection fraction
(HFREF) and patients with heart failure with preserved
ejection fraction (HFPEF) were included. HFPEF is
defined according to recent guidelines [15]. Hyperten-
sion was defined as the presence of a persistent systolic
blood pressure >140 mmHg, a diastolic blood pressure
>90 mmHg or the use of medication for the treatment
of elevated blood pressure in combination with a previ-
ous made diagnosis of hypertension. The aetiology of
heart failure was divided in ischemic, hypertensive,
valvular or other. Ischemic aetiology was defined as hav-
ing previously had a myocardial infarction, a percutan-
eous coronary intervention, a surgical coronary artery
revascularization, a stenosis of >70% in an epicardial ves-
sel on coronary angiography or the presence of ischemia
on nuclear testing. The Medical-Ethical Committee of
both the University Medical Centre Utrecht and the Me-
ander Medical Centre (no. 05/220) approved the proto-
col of the study. Procedures were in accordance with the
Helsinki Declaration and all patients gave written
informed consent.
Magnetic Resonance Imaging: acquisition protocol
Cardiovascular Magnetic Resonance Imaging and mag-
netic resonance angiography (MRA) of the renal arteries
were performed on a 1.5 Tesla Philips Intera (Philips
Medical Systems, Best, the Netherlands). Both the heart
and the renal arteries were assessed in a 45-minute
protocol. The patient was placed in the supine position
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lysis and a circularly polarized spine coil in longitudinal
direction over the area of the kidneys below the cardiac
coil for MRA of the renal arteries.
ECG-triggered breath hold multiphase steady-state
free procession (SSFP) images were acquired in the four-
chamber, short-axis, and two- chamber view scans of the
left ventricle. The short axis plane covered both ventri-
cles from apex to base using 8-mm slices without inter-
slice gap with the following scan parameters: TR/TE 4.0/
2.0 ms, flip angle 50, FOV 350–400, matrix 256x256,
voxel size 1.6x1.6x8.0 mm.
Gadolinium-based contrast (Dotarem, Geurbet,
France) was administered intravenously to first obtain
MRA of the renal arteries at the time of injection (first
pass) and 15 minutes later delayed enhancement scans
of the heart. For MRA of the renal arteries a standard
breath hold 3D T1 contrast-enhanced MRA technique
was used. Scan parameters: TR/TE 3.7/1.33 ms, flipangle
25, FOV 430x430x75, voxel size 0.8x0.8x1.5 mm.
For the delayed enhancement of the heart, breath hold
inversion recovery T1 pulse images were acquired in
four-chamber, short axis and left two-chamber view.
Scan parameters: TR/TE 4.4/1.3 ms, flipangle 15, FOV
410x410x80, matrix 300x169, voxel size 1.4x1.4x5.0 mm.
There were no complications related to the MRI proce-
dures, and all patients tolerated the procedure well.
Magnetic Resonance Imaging: analysis
The SSFP cine short axis scans were used to acquire
measurements of the left ventricle end diastolic volume
(EDV), end systolic volume (ESV), ejection fraction (EF)
and wall mass (EasyVision release 4 cardiac package,
Philips Medical Systems). Endocardial and epicardial
contours were traced manually on the stack of contigu-
ous short-axis cine-images at end-diastole. This tech-
nique has been validated, with high accuracy and
reproducibility [16]. A trained investigator (ME) per-
formed the quantitative image analyses.
Assessment of segmental wall motion and late gadolin-
ium enhancement (LGE) was performed by two inde-
pendent investigators, blinded for clinical data (BV and
YA). The left ventricle was divided in 17 segments
according to standardized nomenclature [17] and
described as either normal, hypokinetic, akinetic, dyski-
netic or aneurysmatic. Enhancing areas of the myocar-
dial wall were identified as fibrotic areas, and separated
into probable previous myocardial infarctions (subendo-
cardial to transmural location) or non-ischemic enhan-
cing wall abnormalities (midwall or subepicardial
location). To quantify the extent and/or transmurality of
the scar tissue, we used the following definitions; a.
spatial extent; the number of affected segments; b. trans-
murality; the number of affected segments withhyperenhancement score of 3 or higher and; c, the total
scar score; the summed segmental scores per patient
divided by 17 (reflecting the damage for each patient)
[18]. Late enhancement was estimated by using a
5-group classification according to the degree of left
ventricle wall involvement with 0, absence of hyperen-
hancement, 1, hyperenhancement of 1% to 25% of left
ventricle wall thickness; 2, hyperenhancement of 26% to
50%; 3, hyperenhancement extending from 51% to 75%;
4, hyperenhancement extending 76% to 99% and 5,
hyperenhancement extending 100%.
The number of renal arteries as well as patency and
presence or absence of stenosis was assessed by two in-
dependent investigators, blinded for clinical and cMRI
data (JV and LM). Stenosis was graded as: no stenosis,
<50% stenosis, 50-70% stenosis, 70-99% stenosis, occlu-
sion 100% or previous stent placement. The presence of
a renal artery stenosis was defined as having a stenosis
>50% or previous renal revascularization, conform cri-
teria from the Stenting in Renal dysfunction caused by
atherosclerotic Renal Artery Stenosis [19].
Statistical analysis
Data are presented as medians with inter-quartile
ranges (IQR) for non-normally distributed variables and
means ± standard deviation (SD) for normally distribu-
ted continuous variables. Differences between groups
were compared with the χ2 test, Mann–Whitney U test
or the Kruskal-Wallis one-way ANOVA when appropri-
ate. Differences were considered significant when
P < 0.05. For statistical analyses the Statistical Package




The original study population of the EPOCARES study
comprised of 62 patients. Five patients withdrew their
informed consent and one patient was excluded due to a
suspected malignancy (diagnosed on routine X-ray at
baseline). Of the 56 patients that eventually participated
in the study, 37 patients underwent a cMRI/MRA. Nine-
teen patients did not undergo cMRI/MRA due to pres-
ence of cardiac implantable electronic devices (n = 15),
orthopnoea (n = 2), claustrophobia (n = 1) or a
GFR < 30 ml/min (n = 1). These data are obtained after
run in treatment with optimal medical therapy for CHF
and oral iron supplementation, but before treatment
with EPO. Clinical characteristics of these 37 patients
are shown in Table 1. The clinical characteristics of the
patients that underwent cMRI/MRA did not differ from
those patients that did not undergo cMRI/MRA. Overall,
patients had markedly reduced eGFR and LVEF. The
majority of patients were using a renin-angiotensin




Atherosclerotic renal artery stenosis p-value
Present(n = 21) Absent(n = 16)
Age, years 74 [68–80] 74 [70–79] 74 [60–82] 0.83
Male sex, no. (%) 23 (62.2) 13 (61.9) 10 (62.5) 0.97
Body mass index (kg/m2) 26.5 ± 4.2 26.3 ± 3.5 26.8 ± 5.1 0.84
Creatinine, umol/L 190 ± 81 204 ± 83 172 ± 77 0.19
Cockcroft Gault (ml/min) 37.4 ± 15.6 33.1 ± 12.3 42.9 ± 18.1 0.07
Haemoglobin (g/dL) 11.7 ± 0.82 11.7 ± 0.81 11.7 ± 0.86 0.58
CRP (mg/L) 5 [1.0-10.5] 5 [1.5-9.5] 4.5 [1.0-11.3] 0.95
hsCRP (mg/L) 4.0 [1.3-9.9] 3.8 [1.3-8.3] 5.8 [0.7-10.4] 0.89
NTproBNP (pg/mL) 1400 [621–2499] 1680 [653–2229] 1360 [503–2853] 0.71
Micro albuminuria (mg/24 h) 21.0 [10.3-218.0] 41.5 [14.5-230.0] 12.5 [8.5-93.8] 0.25
SBP, mmHg 145 ± 21.8 150± 21.6 138 ± 20.9 0.12
DBP, mmHg 75± 11.5 76 ± 13.2 72 ± 8.6 0.23
24-h SBP, mmHg 127 ± 15.3 126± 13.1 128 ± 18.3 0.73
24-h DBP, mmHg 66 ± 8.2 66 ± 8.3 66 ± 8.3 1.00
No. of antihypertensive drugs 3.5 [3.0-4.0] 3.3 [3.0-4.0] 3.8 [2.3-5.0] 0.37
RAS inhibitor
n (%) 36 (97.3) 21 (100.0) 15 (93.8) 0.25
% of recommended dose/day 50 [38–100] 50 [50–100] 75 [25–138] 0.80
β-blocker use, no. (%) 30 (81.1) 16 (76.2) 14 (87.5) 0.38
Diuretic use, no. (%) 29 (78.4) 16 (76.2) 13 (81.3) 0.71
Loop diuretic, no. (%) 24 (64.9) 12 (57.0) 12 (75.0) 0.26
Loop diuretic, dose/day* 40 [0–80] 40 [0–40] 40 [20–110] 0.17
Aldosterone antagonist, no. (%) 5 (13.5) 3 (23.8) 2 (12.5) 0.42
Statin use, no. (%) 28 (75.7) 15 (71.4) 13 (81.3) 0.49
Diabetes, no. (%) 14 (37.8) 5 (23.8) 9 (56.3) 0.04
Hypertension, no. (%) 29 (78.4) 18 (85.7) 11 (68.8) 0.21
Smoking history, no. (%) 24 (64.9) 15 (71.4) 9 (56.3) 0.38
Pack years 16.4 [0–31] 16.4 [0–33] 11.5 [0–30] 0.34
Cerebrovascular disease, no. (%) 7 (18.9) 6 (28.6) 1 (6.3) 0.11
Peripheral arterial disease, no. (%) 14 (37.8) 11 (52.4) 3 (18.8) 0.05
Kidney length (cm) (n = 34) 10.9 ± 4.7 10.3 ± 2.2 11.5 ± 6.5 0.85
Aetiology of heart failure: 0.58
Ischemic, no. (%) 22 (59.5) 13 (61.9) 9 (56.3)
Hypertensive, no. (%) 5 (13.5) 3 (14.3) 2 (12.5)
Valvular, no. (%) 4 (10.8) 3 (14.3) 1 (6.3)
Other, no. (%) 6 (16.2) 2 (9.5) 4 (25.0)
NYHA class 0.21
II, no. (%) 27 (73.0) 17 (80.9) 10 (62.5)
III/IV, no. (%) 10 (27.0) 4 (19.0) 6 (37.5)
Mean± standard deviation or median [interquartile range] is shown.
Abbreviations; CRP, C-reactive protein; hsCRP, high sensitive CRP; NTproBNP, N-terminal pro-brain natriuretic peptide; SBP, systolic blood pressure; DBP, diastolic
blood pressure; RAS inhibitor, renin-angiotensin-system inhibitor; NYHA, New York Heart Association class for heart failure.
• Loop diuretic dose/day of furosemide, bumetanide was converted to 1 mg bumetanide = 40 mg furosemide.
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hypertension and/or diabetes mellitus.
Renal artery stenosis
Of the 37 patients that underwent cMRI/MRA, 21
patients (56.8%) had a renal artery stenosis defined as
>50% stenosis. A more severe stenosis, defined as >70%,
was present in 8 (21.6%) patients. A bilateral ARAS
(>50%) was present in 7 (18.9%) patients. All stenosis
were of atherosclerotic origin. One patient (2.7%) was
previously treated bilaterally by angioplasty with stent
placement. Baseline demographic, clinical and laboratory
characteristics of the patients, divided up by the pres-
ence or absence of ARAS, defined as >50% stenosis, are
provided in Table 1. There were no differences in age,
sex, smoking, the amount of pack years, and the aeti-
ology and severity of heart failure (NYHA class and
NTproBNP levels) between patients with ARAS versus
those without ARAS. Although there seems to be a ten-
dency for a higher systolic blood pressure based on the
office measurements, there is no statistically significant
difference in the averaged 24-hour ambulatory blood
pressure measurements. The number of antihypertensive
drugs in patients with and without ARAS did not differ.
Diabetes mellitus was significantly more prevalent in
patients without ARAS (Figure 1). We did not find aFigure 1 Number of patients with and without diabetes
mellitus (DM), divided by the presence of atherosclerotic renal
artery stenosis (ARAS) in patients with combined chronic heart
failure and chronic kidney disease. *p = 0.04.significant difference in renal function when patients
with and without ARAS were compared. Nonetheless,
the renal function did significantly decline as the severity
of ARAS increased, (ANOVA; p = 0.03); patients with a
unilateral ARAS of >70% or with bilateral ARAS had a
lower GFR (Table 2 and Figure 2). However, there were
no other differences in clinical profile between patients
with a moderate ARAS (>50%, less than 70% stenosis)
versus those with a more severe ARAS (>70% stenosis)
(data not shown). The doses/day for RAS inhibition and
loop diuretics were not different between patients with
and without ARAS. There were also no apparent differ-
ences in medication profile between patients with more
or less severe ARAS.
Cardiac magnetic resonance imaging
Data regarding cMRI are shown in Table 3. Although
the average LVEF by cMRI was 43.3% in the study popu-
lation, 8 patients (21.6%) had an LVEF >50%, underlining
the fact that many patients with combined CHF and
CKD have HFPEF. There were no differences between
patients with versus those without ARAS regarding
LVEF, left ventricular volume or the left ventricular mass
index. LGE was present in 27 of the 37 patients (73%).
In 24 of these 27 patients the LGE was subendocardial
or transmural, determined as ischemic LGE. Non-
ischemic LGE (midwall or subepicardial) was present in
6 patients; 4 patients had hypertensive heart failure, 1
patient had severe valvular disease and 1 patient had
previously had a myocarditis. In 2 of the 4 patients with
hypertensive heart failure, there was both midwall and
subendocardial LGE present, as was the case in the pa-
tient with myocarditis. Based on baseline clinical data,
only 22 of the 24 patients with ischemic LGE were
known with CHF with ischemic aetiology. There was no
difference in the presence and the extent of LGE in
patients with ARAS when compared to those without
ARAS (Table 3). Nor was there a difference between the
two groups regarding the presence and the extent of is-
chemic LGE versus non-ischemic LGE.
Discussion
Our study shows a high prevalence (56.8%) of athero-
sclerotic renal artery stenosis (ARAS) in patients with
combined heart and renal failure, defined as having a
stenosis >50%. When taken a stricter cut-point (> 70%
stenosis) the prevalence of ARAS was still as high as
21.8% in this population. The presence of ARAS was
not associated with the extent in abnormalities in left
ventricular function or myocardial fibrosis based on
cardiac MRI findings with late gadolinium enhance-
ment (LGE), when compared to patients with com-
bined CHF/CKD without ARAS. Neither did we
observe a difference in the presence of an ischemic
Table 2 Clinical variables of patients with combined chronic heart failure and chronic kidney disease, according to









bilateral PTA (n= 8)
p-value
Cockcroft Gault (ml/min) 42.9 ± 18.1 46.4 ± 10.2 30.1 ± 11.3 27.9 ± 8.9 0.01
RAS inhibitor:
No. (%) 15 (94) 5 (100) 8 (100) 8 (100) 0.72
% of recommended dosage/day 75 [25–138] 50 [38–125] 58 [31–100] 50 [50–100] 0.99
diuretic use, no. (%) 13 (81) 3 (60) 7 (88) 6 (75) 0.68
Loop diuretic, dosage/day* 40 [20–110] 40 [0–120] 40 [10–40] 10 [10–70] 0.43
Mean± standard deviation or median [interquartile range] is shown.
Abbreviations: RAS inhibitor, renin-angiotensin-system inhibitor.
* loop diuretic dose/day of furosemide, bumetanide was converted to 1 mg bumetanide = 40 mg furosemide.
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ation between eGFR and the severity of ARAS and
observed a negative association between diabetes melli-
tus and ARAS. This could indicate that our small co-
hort may consist of two different groups of cardiorenal
patients: non-diabetic patients in which ARAS is highly
prevalent and diabetic patients with a much lower
ARAS prevalence.
ARAS is very common in patients with manifestations
of non-renal atherosclerosis, particularly in patients with
peripheral arterial and aortic disease. A recent literature
review found a pooled prevalence of 25.3% in patients
with peripheral arterial disease and 33.1% in patients
with aortic aneurysm [7]. Only few, small, studies deter-
mined the prevalence of ARAS in patients with CHF.
McDowall et al. reported a prevalence of 34% of ARASFigure 2 Comparison of Cockcroft Gault equation (ml/min) in patient
divided by increasing severity of atherosclerotic renal artery stenosisin patients with CHF and deSilva et al. found a preva-
lence of up to 54% [9,20]. In both studies, ARAS was
defined as a stenosis of >50% by magnetic resonance
angiography (MRA). About the prevalence of ARAS in
combined CHF/CKD, even fewer studies are published.
DeSilva et al. reported a prevalence of 68% in 97 patients
with CHF that had renal dysfunction. The study by
deSilva et al. included only patients with HFREF. How-
ever, HFPEF is known to have a similar poor prognosis
as HFREF and to be more prevalent in older patients
and in patients with diabetes and/or hypertension
[21,22]. Our study included an ambulant stable out-
patient clinic patient population with combined chronic
heart failure and chronic kidney disease and mild an-
aemia. We included patients both with HFREF and
HFPEF, treated with renin angiotensin (RAS) inhibitorss with combined chronic heart failure and chronic kidney disease,
. (Shown: median and interquartile range).
Table 3 Cardiac magnetic resonance imaging findings in patients with combined chronic heart failure and chronic
kidney disease
Cardiac MRI parameter All patients
(n = 37)
Atherosclerotic renal artery stenosis p-value
Present(n = 21) Absent(n = 16)
LVEF (%) 43.3 ± 11.2 46.1 ± 9.1 40.2 ± 12.7 0.15
LVESV (ml) 101 [81.8 -127.9] 96 [81.7 – 114.4] 115 [81.4 – 177.0] 0.19
LVEDV (ml) 186 [153.8 - 206.2] 173 [156.4 - 202.3] 197 [138.5 - 279.0] 0.60
LV mass index (g/m2) 49 [43.0 - 59.7] 46 [43.2 - 53.3] 60 [41.7 - 69.0] 0.11
Cardiac output (l/min) 5.4 ± 1.85 5.3 ± 1.16 5.5 ± 2.44 0.72
Cardiac index (l/min/m2) 2.7 ± 0.75 2.7 ± 0.62 2.6 ± 0.90 0.65
Late gadolinium enhancement
Spatial extent 3.5 [1.0 - 6.0] 4.0 [0.5 - 6.0] 3.0 [2.0 - 6.5] 0.65
Transmurality 2.0 [0–4.0] 2.0 [0.0 - 4.0] 2.0 [0.0 - 4.5] 0.89
Total scar score 0.56 [0.12 - 0.99] 0.71 [0.09 – 1.03] 0.35 [0.18 - 0.88] 0.80
Mean± standard deviation or median [interquartile range] is shown.
Abbreviations; LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume; LVEDV, left ventricular diastolic volume; LV mass, left ventricular
mass.
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cohort we demonstrate a high prevalence of ARAS
(56.8%). A more severe degree of ARAS, defined as a
unilateral stenosis of >70% and/or bilateral stenosis
>50% was found in 43.2% of the patients. These results
are similar to those of deSilva et al., confirming this high
prevalence of ARAS in combined CHF/CKD in patients
with both HFREF and HFPEF.
According to the present American Heart Association
guidelines for the management of patients with periph-
eral arterial disease, the indication for percutaneous
renal revascularization with stent placement (PTA) of
ARAS is limited to “flash pulmonary oedema, recurrent
episodes of unexplained congestive heart failure or un-
stable angina” [23]. There is debate however whether
PTA could benefit CHF patients with ARAS. In patients
with stable CKD and/or hypertension it has been
reported several times that PTA does not affect renal
function [5,19,24]. On the other hand, a small retro-
spective study showed that in patients referred for renal
revascularization close to one-third had CHF (mainly
HFPEF) and that revascularization was associated with
better control of heart failure [25]. The results of the
sub analysis of the Angioplasty for Renal Artery Lesions
(ASTRAL) study of a predefined group of patients with
CKD and reduced ejection fraction are not yet available.
Nonetheless, diagnosing ARAS can be important for
more reasons than to find patients suitable for PTA.
One could interpret the presence of ARAS as a marker
of “atherosclerotic burden” associated with a high risk of
cardiovascular events, which would warrant more ag-
gressive medical therapy [8]. Indeed, in a follow up study
of elderly people with ARAS, the annual incidence of
coronary events, heart failure and death were as high as
30%, 19% and 17% respectively [26]. A recentretrospective study in elderly patients with ARAS pre-
sented a very high morbidity and mortality (49% suffered
a primary event and 37% died during median follow-up
of 3.3 years), which was negatively associated with the
use of statins.
In addition to determining the prevalence of ARAS in
patients with both CHF and CKD, we determined
whether there is an association between left ventricular
structure and function and the presence of ARAS. Al-
though one could hypothesize that ARAS would be
associated more often, and to a greater extent, with car-
diac abnormalities, such as left ventricular hypertrophy,
we found no differences in left ventricular mass index,
left ventricular volumes and LVEF in patients with and
without ARAS. We also hypothesized that the existence
of ARAS represents an “atherosclerotic burden”, repre-
senting one of the mechanisms of combined CHF/CKD.
However, we found no difference in the presence of is-
chemic aetiology of CHF. Moreover, we could not dem-
onstrate a difference in the presence, the location and
the extent of fibrosis, as depicted by LGE. The study by
Wright et al. showed more diastolic dysfunction and left
ventricular hypertrophy in patients with ARAS when
compared with a matched control group with similar
renal dysfunction [12]. In contrast, our study only
included patients with known CHF and CKD. In those
patients with combined CHF and CKD, the presence of
ARAS was not associated with a more severely impaired
cardiac function, more severe left ventricular hyper-
trophy or the presence of fibrosis.
Coincidentally we found a negative association be-
tween diabetes and ARAS; the patients with combined
CHF/CKD without ARAS were markedly more likely to
have diabetes mellitus than those patients with ARAS
(Figure 1). Some studies identified diabetes mellitus as a
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diabetes mellitus was not associated with ARAS [28,29].
The negative association between diabetes and ARAS
may point to a mechanistic difference in the pathophysi-
ology of combined CHF/CKD in patients with and with-
out diabetes. However, alternatively, the difference may
result from survival bias.
A point of debate is the definition of ARAS, since no
uniform definition exists. Previously, most studies
defined ARAS as >50% stenosis [19,24,30-32]. Indeed,
the American Heart Association Guidelines [23] are
based on studies using this definition. However, more re-
cent guidelines from the European Society of Cardiology
define ARAS as having a stenosis >60% [33], based on
the fact that MRA (and CT angiography) tend to over-
estimate the degree of stenosis. More recent PTA studies
often combine this definition with additional haemo-
dynamic measurements, e.g. a systolic pressure gradient
[34], measurement of the fractional flow reserve [35] or
use a more strict cut-point of >70%. In this study we
used the definition of ARAS as defined >50%, in accord-
ance with the STAR study [19]. However, if we also
apply the more stringent definition of >70% stenosis we
still find a prevalence of 21.8% of ARAS. Except for a
significant decline in renal function in patients with a
more severe ARAS versus a moderate ARAS, we found
no other differences in clinical profile between a moder-
ate or severe ARAS.
Some limitations of this study need to be acknowl-
edged. The small study population, due to the complex-
ity of the study design, consists of a selected group of
stable ambulant patients, almost all using RAS inhibitors
which, in addition to the exclusion of uncontrolled
hypertension and patients with flash pulmonary oedema,
may have led to underestimation of the prevalence of
ARAS in CRS. However, despite this small study popula-
tion, we believe that these data are valuable and robust,
due to a paucity of data in the present literature about
this subject and the reliable assessment with cardiac
MRI. Furthermore, the data are baseline data from a
randomized intervention study, which precludes spon-
taneous follow-up.Conclusion
In conclusion, ARAS is prevalent in patients with
combined CHF and CKD and its presence does not
correlate with worse left ventricular function, left ven-
tricular volumes, mass, nor myocardial fibrosis as
assessed by MRI. However, the severity of ARAS is
weakly associated with renal dysfunction and ARAS is
remarkably negatively associated with diabetes mellitus
in this cohort. Further research is needed to investigate
its role in the pathophysiology of combined chronicheart failure and chronic kidney disease and subse-
quent therapeutic consequences.
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